GO:0170047 virus-like capsid: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0170047 virus-like capsid describes a protein coat that surrounds nucleic acid to form a non-infectious structure similar to a virus capsid, encoded by endogenous non-viral genes.
• Virus-like capsids are best known from the Arc gene, whose protein self-assembles into capsid-like structures that encapsulate Arc mRNA and mediate intercellular RNA transfer.
• The same self-assembly principle is exploited in biotechnology to produce virus-like particles (VLPs) for vaccines and gene delivery.
• Point mutations in capsid proteins can drive symmetry changes, such as the formation of tetrahedral cages, revealing design rules for engineered capsids.
• VLPs derived from diverse viruses, including papillomavirus, Zika virus, SARS-CoV-2, and coxsackievirus, are immunogenic and protective in animal models.
• Research on virus-like capsids spans structural biology, RNA biology, immunology, and gene therapy, requiring integrated methods such as cryo-EM, RNA-seq, and CRISPR editing.
Description
Virus-like capsids (GO:0170047) are protein coats that enclose nucleic acid to form structures resembling viral capsids but are non-infectious and encoded by endogenous, non-viral genes. This ontology term captures a fundamental cellular component that bridges cell biology, RNA transport, and biotechnology. The definition highlights that proteins such as Arc, which is ancestrally related to retrotransposon Gag, can self-assemble into capsid-like structures that encapsulate Arc mRNA and mediate intercellular transmission of RNA. Understanding virus-like capsids is therefore critical for deciphering how cells exchange genetic information and for harnessing these particles in therapeutic applications. The concept of virus-like capsids has gained prominence through studies of the Arc protein, which forms virion-like capsids in Drosophila and tetrapods. These structures are not infectious but serve as vehicles for RNA transfer between cells, a process implicated in synaptic plasticity and memory. Beyond Arc, many viruses produce virus-like particles (VLPs) when their capsid proteins are expressed alone, and these have been repurposed as vaccines and delivery platforms. For example, papillomavirus L1 protein self-assembles into highly immunogenic VLPs, and engineered VLPs with improved production and transduction efficiencies have been developed through directed evolution. For researchers, GO:0170047 provides a unified framework to study capsid assembly, cargo packaging, and intercellular communication. The term is also relevant to disease, as dysregulation of capsid-forming proteins may contribute to neurodegeneration and cancer. Moreover, VLPs are promising tools for vaccine development and gene therapy, as demonstrated by protective immune responses against Zika, SARS-CoV-2, and coxsackievirus in preclinical models. This article reviews the structure, function, and research methods associated with virus-like capsids, emphasizing real PubMed literature and authoritative GO data.
virus-like capsid At A Glance
| GO ID | GO:0170047 |
|---|---|
| GO term | virus-like capsid |
| Ontology | cellular_component |
| Synonym | virus-like particle |
| Major function | Encapsidation of nucleic acid and intercellular RNA transfer; immunogenic platform for vaccines |
| Definition | A protein coat that surrounds nucleic acid to form a structure similar to a virus capsid; non-infectious and encoded by endogenous genes |
| Example proteins | Arc (fly and tetrapod), papillomavirus L1, Zika virus capsid, SARS-CoV-2 capsid |
| Assembly property | Self-assembly of capsid proteins into higher-order structures; symmetry can be altered by point mutations |
| Biotechnological use | VLP vaccines, gene delivery vectors, and armored particles |
What Is GO:0170047?
A virus-like capsid is a protein shell that encloses nucleic acid to form a structure similar to a virus capsid, but it is non-infectious and is encoded by endogenous, non-viral genes. These capsids self-assemble from proteins such as Arc, which is related to retrotransposon Gag, and can encapsulate mRNA for intercellular transport. The term is synonymous with virus-like particle (VLP) in many contexts.
Why Is virus-like capsid Important in Cell Biology?
Virus-like capsids are important because they represent a fundamental mechanism for packaging and transferring RNA between cells, with roles in neuronal function and disease. They also provide a versatile platform for vaccine development and gene therapy, as VLPs can elicit strong immune responses and deliver cargo. Understanding their assembly and regulation can lead to new treatments for infectious diseases, cancer, and neurological disorders.
• Arc-mediated virus-like capsids facilitate intercellular RNA transfer, impacting synaptic plasticity and memory.
• VLPs are highly immunogenic and are used in licensed vaccines, such as HPV vaccines.
• Engineered VLPs with improved production and transduction efficiencies are being developed for gene therapy.
• Point mutations in capsid proteins can drive symmetry reduction, enabling design of custom cages.
• VLP-based vaccines protect against Zika, SARS-CoV-2, and coxsackievirus in animal models.
• Virus-like capsids from insect viruses, such as BmCPV, inform understanding of capsid assembly.
• Armored VLPs with endoskeletons show enhanced stability for delivery applications.
• Dysregulation of capsid-forming proteins like Arc is linked to neurodegeneration and cancer.
• CRISPR screening can identify host factors required for VLP production and function.
• Virus-like capsids are model systems for studying protein self-assembly and RNA packaging.
Structure, Assembly, and Molecular Mechanism of virus-like capsid
Self-assembly of capsid proteins
In simple terms: Capsid proteins spontaneously come together to form a shell.
Virus-like capsids self-assemble from individual protein subunits into higher-order structures. For example, papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Similarly, Arc protein self-assembles into capsid-like structures that encapsulate Arc mRNA. This self-assembly is driven by interactions between capsid protein subunits and can be influenced by point mutations that alter symmetry, as shown for a virus-like capsid that forms tetrahedral cages upon mutation.
Nucleic acid encapsidation
In simple terms: The capsid shell packages RNA or DNA inside.
Virus-like capsids surround nucleic acid to form a structure similar to a virus capsid. Arc capsids specifically encapsulate Arc mRNA and mediate its intercellular transmission. In biotechnological applications, VLPs can be engineered to package cargo, and directed evolution has improved their production and transduction efficiencies. The encapsidation process often relies on electrostatic interactions between the capsid interior and the nucleic acid cargo.
Intercellular transmission
In simple terms: Capsids can carry RNA from one cell to another.
Arc-containing virus-like capsids mediate the intercellular transmission of RNA, a process that may contribute to cell-to-cell communication in the nervous system. This transfer is non-infectious and distinct from viral infection. The mechanism involves release of capsids from donor cells and uptake by recipient cells, where the encapsulated RNA can be translated or otherwise functional.
Symmetry and structural variation
In simple terms: The shape of the capsid can change with small mutations.
The overall architecture of virus-like capsids is determined by the arrangement of protein subunits. A point mutation in a virus-like capsid can drive symmetry reduction to form tetrahedral cages, demonstrating that subtle sequence changes can dramatically alter quaternary structure. This principle is exploited in protein engineering to design capsids with tailored geometries.
Immunogenicity and vaccine applications
In simple terms: Capsids can trigger strong immune responses.
Virus-like capsids are highly immunogenic because their repetitive, ordered surface displays antigens effectively. VLP-based vaccines against Zika virus, SARS-CoV-2, and coxsackievirus B1 induce high levels of neutralizing antibodies and protect animals from infection. For example, a capsid VLP-based SARS-CoV-2 vaccine induced high antibody levels and protected rhesus macaques. A coxsackievirus B1 VLP vaccine modified to exclude an immunoreactive region induced potent neutralizing antibodies and protected mice.
Engineering and stabilization
In simple terms: Scientists modify capsids to make them more stable or useful.
Directed evolution has been used to engineer virus-like particles with improved production and transduction efficiencies. Additionally, VLPs can be armored by an endoskeleton to enhance their stability and functionality. These engineering efforts expand the utility of virus-like capsids in gene delivery and vaccination.
Key Genes Involved in GO:0170047 virus-like capsid
The following genes and proteins are central to the study of virus-like capsids, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Arc | Self-assembles into capsid-like structures; encapsulates Arc mRNA; mediates intercellular RNA transfer | Key model for endogenous virus-like capsids; implicated in synaptic plasticity and memory |
| L1 (HPV) | Major capsid protein that self-assembles into VLPs | Basis for HPV vaccines; model for VLP immunogenicity |
| Zika virus capsid | Forms VLPs when expressed in stable cell lines | Vaccine development against Zika virus |
| SARS-CoV-2 capsid | Capsid protein used to generate VLPs | VLP-based COVID-19 vaccine candidate |
| Coxsackievirus B1 capsid | Capsid proteins assemble into VLPs | VLP vaccine against coxsackievirus B1 |
| BmCPV capsid shell protein | Assembles with large protrusion protein to form VLPs | Model for insect virus capsid assembly |
| Gag (retrotransposon) | Ancestral relative of Arc; forms capsids | Evolutionary link to virus-like capsids |
| Engineered VLP variants | Directed evolution to improve production and transduction | Gene therapy and vaccine delivery |
| Tetrahedral cage mutants | Point mutations that reduce symmetry | Protein design and structural biology |
| Endoskeleton-armored VLPs | Enhanced stability through internal scaffolding | Delivery applications |
| Papillomavirus L1 variants | Self-assemble into immunogenic VLPs | Vaccine development |
| Zika capsid stable cell line | Constitutive VLP production | Scalable vaccine manufacturing |
| SARS-CoV-2 VLP immunogens | Display spike or other antigens | Induction of neutralizing antibodies |
| Coxsackievirus B1 modified VLP | Excludes immunoreactive region | Improved neutralizing antibody response |
| BmCPV large protrusion protein | Co-expression with capsid shell protein | VLP assembly studies |
| Arc mRNA | Cargo encapsulated by Arc capsids | Intercellular RNA transfer |
| Retrotransposon Gag | Ancestral capsid-forming protein | Evolution of virus-like capsids |
| Engineered capsid proteins | Designed for improved properties | Synthetic biology and nanomedicine |
How Is virus-like capsid Regulated?
The assembly and function of virus-like capsids can be regulated at multiple levels. For Arc, neuronal activity induces Arc expression, which then self-assembles into capsids. The stability and release of capsids may be influenced by post-translational modifications and cellular trafficking pathways, though specific regulators are still being elucidated. In biotechnological contexts, production of VLPs can be optimized by modifying expression conditions and using directed evolution to select for improved variants. Additionally, the immunogenicity of VLPs can be modulated by altering surface-exposed regions, as shown for coxsackievirus B1 VLPs modified to exclude a highly conserved immunoreactive region.
virus-like capsid and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Arc | Neurodegeneration, synaptic plasticity | Arc knockout mice; neuronal cultures; RNA transfer assays |
| HPV L1 | Cervical cancer | VLP-based prophylactic vaccine; mouse immunization |
| Zika capsid | Zika virus infection | Stable cell line producing VLPs; mouse challenge |
| SARS-CoV-2 capsid | COVID-19 | VLP vaccine; rhesus macaque challenge |
| Coxsackievirus B1 capsid | Coxsackievirus infection | Modified VLP vaccine; mouse protection |
Neurodegeneration and Arc dysfunction
Arc is a key protein that forms virus-like capsids and is critical for synaptic plasticity and memory. Dysregulation of Arc has been implicated in neurodegenerative disorders such as Alzheimer's disease, where altered Arc function may contribute to synaptic loss. The capsid-forming property of Arc suggests that defects in RNA transfer could underlie aspects of neurodegeneration, although direct evidence is still emerging.
Cancer and VLP-based immunotherapy
Virus-like capsids are being explored as cancer immunotherapy platforms because they can deliver tumor antigens and elicit strong immune responses. For example, HPV L1 VLPs are the basis of prophylactic vaccines that prevent cervical cancer. Engineered VLPs with improved transduction efficiencies may also be used for targeted gene delivery to cancer cells.
Infectious diseases and VLP vaccines
VLP-based vaccines have shown protective efficacy against several infectious diseases. A SARS-CoV-2 VLP vaccine induced high levels of antibodies and protected rhesus macaques. A coxsackievirus B1 VLP vaccine modified to exclude an immunoreactive region induced potent neutralizing antibodies and protected mice. A Zika virus VLP vaccine made from a stable cell line also demonstrated immunogenicity. These examples highlight the therapeutic potential of virus-like capsids.
Genetic disorders and gene therapy
Engineered virus-like particles are being developed as gene delivery vehicles for genetic disorders. Directed evolution has improved their production and transduction efficiencies, making them promising alternatives to viral vectors. Armored VLPs with endoskeletons may offer enhanced stability for in vivo delivery.
From virus-like capsid-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does Arc mediate intercellular RNA transfer? | Arc knockout and tagged knock-in in neuronal cells |
| Can point mutations alter capsid symmetry? | Point-mutation knock-in of capsid genes in cell lines |
| Can VLPs be engineered for improved production? | Directed evolution and overexpression of capsid variants |
| Are VLPs immunogenic and protective? | Knock-in of antigen genes into VLP-producing cells; animal immunization |
| What is the structure of virus-like capsids? | Tagged knock-in for cryo-EM and structural studies |
| Can VLPs deliver cargo to specific cells? | Overexpression of engineered capsids; transduction assays |
How to Study the virus-like capsid Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | High-resolution structure of capsids | Determining assembly and symmetry |
| RNA-seq | RNA cargo encapsulated by capsids | Identifying packaged mRNAs |
| RIP-seq | RNA-protein interactions | Mapping Arc mRNA binding |
| Mass spectrometry | Protein composition of VLPs | Identifying capsid-associated proteins |
| ELISA | Antibody titers against VLP antigens | Vaccine immunogenicity |
| Neutralization assay | Functional antibody response | Evaluating protective immunity |
| Animal challenge | Protection against infection | Preclinical vaccine efficacy |
| Directed evolution | Improved VLP production and transduction | Engineering gene delivery vectors |
Structural biology (cryo-EM, X-ray crystallography)
Cryo-electron microscopy and X-ray crystallography are used to determine the high-resolution structures of virus-like capsids. These methods revealed that a point mutation in a virus-like capsid drives symmetry reduction to form tetrahedral cages. Structural studies of BmCPV capsid proteins also provide insights into assembly.
RNA sequencing and RNA immunoprecipitation
RNA-seq and RNA immunoprecipitation (RIP) can identify nucleic acids encapsulated by virus-like capsids. For example, Arc capsids encapsulate Arc mRNA, which can be detected by RIP followed by sequencing. These methods are essential for understanding cargo specificity.
Proteomics and mass spectrometry
Mass spectrometry-based proteomics can identify proteins that co-assemble with capsids or are packaged inside. This approach helps define the composition of VLPs and identify host factors involved in assembly.
Immunological assays and animal models
ELISA, neutralization assays, and animal challenge studies are used to evaluate the immunogenicity and protective efficacy of VLP vaccines. For example, a SARS-CoV-2 VLP vaccine induced high antibody levels and protected rhesus macaques, and a coxsackievirus B1 VLP vaccine protected mice.
How CRISPR Can Be Used to Study GO:0170047 virus-like capsid
Knockout
CRISPR knockout of genes encoding capsid proteins or host factors can reveal their essential roles in virus-like capsid assembly and function. For example, knocking out Arc in neurons would test its requirement for intercellular RNA transfer. Knockout of host genes identified by screening can also uncover dependencies for VLP production.
Point Mutation
CRISPR-mediated point mutations can be introduced to study the effect of specific amino acid changes on capsid assembly and symmetry. A point mutation in a virus-like capsid was shown to drive symmetry reduction to form tetrahedral cages. Such models are valuable for structure-function studies.
Knock-in
Knock-in of tags or reporter genes into capsid loci allows visualization and purification of virus-like capsids. Tagged knock-in of Arc, for example, enables tracking of Arc capsids in neurons. Knock-in of antigen genes into VLP-producing cell lines can create customized vaccines.
Overexpression
Overexpression of capsid proteins is commonly used to produce VLPs for structural and immunological studies. For instance, overexpression of papillomavirus L1 leads to self-assembly of VLPs. Overexpression of engineered capsid variants can improve production yields and transduction efficiencies.
How EDITGENE Supports virus-like capsid Research
Researchers studying virus-like capsid-related genes often need to determine whether a candidate gene is causally involved in capsid assembly, cargo packaging, or intercellular transfer. EDITGENE provides comprehensive CRISPR services to create precise cellular models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for virus-like capsid research.
Frequently Asked Questions About virus-like capsid
What is a virus-like capsid?
A virus-like capsid is a protein coat that surrounds nucleic acid to form a structure similar to a virus capsid, but it is non-infectious and encoded by endogenous genes.
What genes are involved in virus-like capsid formation?
Key genes include Arc, which self-assembles into capsids, and viral capsid proteins such as papillomavirus L1, Zika capsid, and SARS-CoV-2 capsid.
What is the function of virus-like capsids?
They encapsulate nucleic acids and can mediate intercellular RNA transfer, as shown for Arc, and are used in vaccines and gene delivery.
How are virus-like capsids studied?
Methods include cryo-EM, RNA-seq, proteomics, and immunological assays.
What diseases are associated with virus-like capsids?
They are linked to neurodegeneration through Arc, and are used in vaccines against infectious diseases like COVID-19 and Zika.
Can virus-like capsids be engineered?
Yes, directed evolution and point mutations can alter their properties, such as production efficiency and symmetry.
What is the difference between a virus-like capsid and a virus?
Virus-like capsids are non-infectious and encoded by endogenous genes, whereas viruses are infectious and encode their own replication machinery.
What is Arc and its role in virus-like capsids?
Arc is a neuronal protein that self-assembles into capsid-like structures and encapsulates Arc mRNA for intercellular transfer.
Are virus-like capsids used in vaccines?
Yes, VLP-based vaccines are used or in development for HPV, Zika, SARS-CoV-2, and coxsackievirus.
How can CRISPR help study virus-like capsids?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of capsid genes to study their function.
Conclusion
Virus-like capsids (GO:0170047) are endogenous protein coats that encapsulate nucleic acids and mediate intercellular RNA transfer, with Arc as a paradigm. They also serve as versatile platforms for vaccines and gene delivery, as demonstrated by protective VLP vaccines against multiple pathogens. Continued research using CRISPR models and advanced structural and functional methods will further illuminate their biology and therapeutic potential.
References
- 1. Kirnbauer R et al.. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.. Proc Natl Acad Sci U S A 89(24):12180-4 PMID: 1334560
- 2. Raguram A et al.. 2025. Directed evolution of engineered virus-like particles with improved production and transduction efficiencies.. Nat Biotechnol 43(10):1635-1647 PMID: 39537813
- 3. Szyszka TN et al.. 2024. Point mutation in a virus-like capsid drives symmetry reduction to form tetrahedral cages.. Proc Natl Acad Sci U S A 121(20):e2321260121 PMID: 38722807
- 4. Volkmann A et al.. 2022. A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques.. Front Immunol 13:857440 PMID: 35479095
- 5. Soppela S et al.. 2025. Coxsackie B1 virus-like particle vaccine modified to exclude a highly conserved immunoreactive region from the capsid induces potent neutralizing antibodies and protects against infection in mice.. J Biomed Sci 32(1):86 PMID: 40922007
- 6. Garg H et al.. 2019. Capsid containing virus like particle vaccine against Zika virus made from a stable cell line.. Vaccine 37(48):7123-7131 PMID: 31607605
- 7. Ren F et al.. 2022. Characterization of virus-like particles assembled by co-expression of BmCPV capsid shell protein and large protrusion protein.. Int J Biol Macromol 209(Pt B):1656-1664 PMID: 35460752
- 8. Wu Z et al.. 2024. Virus-like Particles Armored by an Endoskeleton.. Nano Lett 24(10):2989-2997 PMID: 38294951
